Table 4.

EBNA-1 and VCA IgG titers at baseline visit (prior DMT onset) and progression, number of relapses, clinical response and therapeutic failure after two years of follow-up with DMT.

	EBNA-1 IgG		VCA IgG
	PROGRESSION		PROGRESSION
	pos./N (%)	Titers*	pos./N (%)	Titers*
YES	51/53 (96.2)	25.7	53/53 (100)	59.1
NO	265/270 (98.1)	25.3	269/270 (99.6)	59.9
p**	n.s.	n.s.	n.s.	n.s.
OR (95% CI)
	RELAPSES		RELAPSES
	pos./N (%)	Titers*	pos./N (%)	Titers*
YES	128/131 (97.7)	25.5	130/131 (99.2)	60.1
NO	190/194 (97.9)	25.3	194/194(100)	59.4
p**	n.s.	n.s.	n.s.	n.s.
OR (95% CI)
	CLINICAL RESPONSE		CLINICAL RESPONSE
	pos./N (%)	Titers*	pos./N (%)	Titers*
YES	165/168 (98.2)	25.3	168/168 (100)	59.7
NO	153/157 (97.5)	25.5	156/157 (99.4)	59.9
p**	n.s.	n.s.	n.s.	n.s.
OR (95% CI)
	THERAPEUTIC FAILURE		THERAPEUTIC FAILURE
	pos./N (%)	Titers*	pos./N (%)	Titers*
YES	92/94 (97.9)	25.6	94/94 (100)	59.0
NO	226/231 (97.8)	25.2	230/231 (99.6)	60.1
p**	n.s.	n.s.	n.s.	n.s.
OR (95% CI)

*Median values of the arbitrary units (AU). **Student t test (for titers) and Chi-square test (for categorical variables). n.s., not significant.